Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Enclosed press release of the same.
The above information is a part of company’s filings submitted to BSE.